Biohaven Pharma Holdings (BHVN) stock had its Relative Strength (RS) Rating upgraded from 86 to 92 Wednesday.
XWhen looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. This proprietary rating measures technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the trailing 52 weeks matches up against all other stocks in our database.
Over 100 years of market history reveals that the top-performing stocks often have an RS Rating north of 80 at the beginning of a new climb.
See How IBD Helps You Make More Money In Stocks
Is Biohaven Pharma Holdings Stock A Buy?
Biohaven Pharma Holdings stock has moved more than 5% past a 93.64 entry in a second-stage double bottom, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
While the biotech company's top line growth fell last quarter from 669% to 441%, EPS grew 13%, up from 0% in the prior report.
Biohaven Pharma Holdings stock holds the No. 76 rank among its peers in the Medical-Biomed/Biotech industry group. Pacira Pharmaceuticals (PCRX), Regeneron Pharmaceutical (REGN) and Vertex Pharmaceuticals (VRTX) are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
YOU MIGHT ALSO LIKE:
MarketSmith's Tools Can Help The Individual Investor
IBD Live: A New Tool For Daily Stock Market Analysis
Profit From Short-Term Trends With SwingTrader
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
The post Biohaven Pharma Holdings Stock Joins Elite Club Of Stocks With RS Ratings Over 90 appeared first on Investor's Business Daily.
from Investor's Business Daily https://ift.tt/JhWQMs0